delapril (cas 110508-92-4) versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy
-
Add time:08/19/2019 Source:sciencedirect.com
Thirty-nine hypertensive patients with type 2 diabetes mellitus were followed under long-term treatment (mean, 20.7 months) with manidipine hydrochloride, a Ca antagonist, or delapril (cas 110508-92-4) hydrochloride, an ACE inhibitor, at nine institutions. Both the treatments showed similar antihypertensive effects, although slight but significantly larger decreases were observed in systolic and mean blood pressures at months 12 and 24 in the patients treated with manidipine (P<0.02). The urinary albumin excretion index (AEI) tended to increase throughout the study in both treatment groups, but no significant difference in AEI was observed between the two treatment groups at any time point. Overt albuminuria developed in four patients on manidipine but did not appear in any of the patients on delapril. The risk of progression to overt albuminuria was significantly different between manidipine and delapril groups (P=0.011). No increase in serum creatinine (Cr) was observed with delapril. The average excretion indexes of tubular markers such as β2-microglobulin, α1-microglobulin, and NAG tended to be higher in the patients on manidipine than in those on delapril. Taken in sum, these findings suggest that the ACE inhibitor delapril is more beneficial than the Ca antagonist manidipine in the treatment of diabetic renal diseases via mechanisms other than the blood pressure regulation, partly through their different effects on tubular function. In conclusion, delapril was significantly more effective than manidipine in inhibiting progression to overt albuminuria in hypertensive type 2 diabetes mellitus patients.
We also recommend Trading Suppliers and Manufacturers of delapril (cas 110508-92-4). Pls Click Website Link as below: cas 110508-92-4 suppliers
Prev:Effects of the fixed combination of manidipine plus delapril (cas 110508-92-4) in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial
Next:delapril (cas 110508-92-4) slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Safety and efficacy study of delapril (cas 110508-92-4) versus enalapril in patients with congestive heart failure08/22/2019
- Congestive heart failure in elderly patients: Controlled study of delapril (cas 110508-92-4) versus captopril08/21/2019
- delapril (cas 110508-92-4) slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits08/20/2019
- Effects of the fixed combination of manidipine plus delapril (cas 110508-92-4) in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial08/18/2019
- Efficacy and safety of delapril (cas 110508-92-4) plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial08/17/2019
- Effect on the development of ankle edema of adding delapril (cas 110508-92-4) to manidipine in patients with mild to moderate essential hypertension: A three-way crossover study08/16/2019
- Rationale for use of the fixed combination of delapril (cas 110508-92-4) and manidipine in the treatment of hypertension in patients with diabetes mellitus08/15/2019
- delapril (cas 110508-92-4) versus enalapril in patients with congestive heart failure08/14/2019
- Original ArticleDissolution method for delapril (cas 110508-92-4) and manidipine combination tablets based on an absorption profile of manidipine☆08/13/2019